View Clinical Trial (Medical Research Study)

A Phase I Study of Topotecan by Intracerebral Clysis for the Treatment of Recurrent Primary Malignant Brain Tumors

This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials

---

Conditions:		Brain Neoplasms, Primary Malignant
Purpose:		This study will evaluate the safety and efficacy of a chemotherapeutic drug (topotecan) as it is given directly into brain tumors by a delivery technique called convection-enhanced delivery. This drug has been used for different types of cancer, but in this study it will be given by an experimental delivery technique designed to maximize the amount of drug delivered to the brain tumor and minimize the side effects in other parts of the body. This study will also evaluate advanced MR imaging techniques. The study will assess quality of life parameters throughout the follow-up period.
Study Summary:		Clinical efficacy with chemotherapy has been discouraging for malignant brain tumors, mostly because of side effects and delivery limitations. Because they are locally invasive and rarely metastasize, malignant gliomas have features that make them uniquely amenable to new strategies of regional drug delivery. Intracerebral clysis (convection-enhanced delivery) is a novel drug delivery strategy that uses a microinfusion pump to establish a pressure gradient in the brain via implanted catheters. The pressure gradient produces convective forces that distribute a therapeutic agent throughout the tumor and surrounding brain tissue. Non-invasive MRI methods of monitoring drug distribution and treatment response have been developed to maximize the clinical applications and minimize complications associated with treatment risks. Study participants will be taken to the operating room to have 2 catheters surgically placed into their tumor and surrounding tumor bed. These catheters will then be connected to small infusion pumps which will slowly infuse topotecan continuously over 4-5 days. Patients will have daily MRI scans while in the hospital. Upon completion of the experimental treatment, patients will be discharged and will be followed up in the outpatient clinic.
Criteria:		Inclusion Criteria: - Single primary malignant brain tumor - Previous treatment with external beam radiation - Tumor is stereotactically accessible - Karnofsky Performance Score at least 60 Exclusion Criteria: - Diffuse subependymal or CSF disease - Tumor involves brainstem, cerebellum or both hemispheres - Active infection - Systemic disease associated with unacceptable anesthetic/operative risk - Previous treatment with topotecan - Unable to receive MRI scans
NCT ID:		NCT00308165
Primary Contact:		Principal Investigator Jeffrey Bruce, MD Columbia University
Backup Contact:		N/A
Location Contact:		New York, New York 10032 United States There is no listed contact information for this specific location. Site Status: N/A

---

---